摘要
目的:评价八珍汤对骨肉瘤患者化疗后的临床疗效。方法:64例骨肉瘤患者随机分为治疗组及对照组,各32例。化疗前后观察八珍汤干预围化疗期患者:(1)外周血象及CD4+/CD8+;(2)升白细胞及升血小板药物的用量;(3)生存质量评分;(4)总生存率和无病生存率。结果:两组化疗后Kf评分、CD4+/CD8+均有明显的下降(P<0.05),八珍汤能降低化疗后患者的Kf积分及CD4+/CD8+下降的幅度(P<0.05);减少化疗过程中升白细胞及升血小板药物的使用量(P<0.05);两组治疗后的总生存率和无病生存率无明显差异(P>0.05)。结论:八珍汤可以减少化疗对骨髓的抑制作用,改善化疗患者的生存质量。
Objective: To evaluate the clinical efficacy of Bazhen Decoction on osteosarcoma after chemotherapy. Method:64 patients were divided into treatment group and control group,32 patients in each group. Before and after chemotherapy,the intervention of Bazhen Decoction was observed,including peripheral blood and CD4^+/ CD8^+,the dosage of leukocyte and blood platelet increasing agent,life quality score,overall survival and disease-free survival. Result: Two groups' Kf score and CD4^+/ CD8^+were significantly decreased( P〈0. 05) after chemotherapy. The prescription can reduce Kf points and CD4^+/ CD8^+( P〈0. 05) and can reduce the dosage of leukocyte and blood platelet increasing agent( P〈0. 05). The overall survival and disease-free survival of two groups had no obvious difference( P〉0. 05). Conclusion:Bazhen Decoction can reduce the inhibitory effect of chemotherapy on bone marrow and improve the patients' quality of1 ife.
出处
《中华中医药学刊》
CAS
北大核心
2015年第4期940-943,共4页
Chinese Archives of Traditional Chinese Medicine
基金
浙江省中医药管理局基金项目(2012ZB131)
关键词
八珍汤
骨肉瘤
化疗
临床观察
Bazhen Decoction
osteosarcoma
chemotherapy
clinical effect observation